Avacta Group PLC Issue of Equity (8245G)
June 01 2017 - 3:56AM
UK Regulatory
TIDMAVCT
RNS Number : 8245G
Avacta Group PLC
01 June 2017
Avacta Group plc
("Avacta", the "Company" or the "Group")
Issue of Equity
Avacta Group plc (AIM: AVCT), the developer of Affimer(R)
biotherapeutics and research reagents, today announces that
following the exercise of employee share options it has issued and
allotted 500 new ordinary shares of 10 pence each in the Company
("Ordinary Shares"). Application has been made for the new Ordinary
Shares to be admitted to trading on AIM and dealings are expected
to commence on 7 June 2017 ("Admission").
Following Admission, the total number of Ordinary Shares with
voting rights in issue will be 68,393,088. Accordingly,
shareholders may use this figure as the denominator for the
calculations by which they will determine if they are required to
notify their interest in, or a change to their interest in the
Company under the FCA's Disclosure Guidance and Transparency
Rules.
- Ends -
For further information:
Avacta Group plc Tel: +44 (0)
Alastair Smith, Chief Executive 844 414 0452
Officer www.avacta.com
Tony Gardiner, Chief Financial
Officer
finnCap Ltd Tel: +44 (0)
Geoff Nash / Giles Rolls - Nominated 207 220 0500
Adviser www.finncap.com
Tim Redfern / Alice Lane - Corporate
Broking
Tel: +44 (0)
WG Partners 203 705 9318
Nigel Birks / Nigel Barnes Tel: +44 (0)
David Wilson / Claes Spang 203 705 9217
www.wgpartners.co.uk
FTI Consulting (Financial Media Tel: +44 (0)
and IR) 203 727 1000
Simon Conway / Natalie Garland-Collins avacta@fticonsulting.com
About Avacta Group plc (www.avacta.com)
Avacta's principal focus is on its proprietary Affimer(R)
technology which is a novel engineered alternative to antibodies
that has wide application in Life Sciences for diagnostics,
therapeutics and general research and development.
Antibodies dominate markets worth in excess of $50bn despite
their shortcomings. Affimer technology has been designed to address
many of these negative performance issues, principally; the time
taken to generate new antibodies, the reliance on an animal's
immune response, poor specificity in many cases, and batch to batch
variability. Affimer technology is based on a small protein that
can be quickly generated to bind with high specificity and affinity
to a wide range of protein targets.
Avacta has a pre-clinical biotech development programme with an
in-house focus on immuno-oncology and bleeding disorders as well as
partnered development programmes. Avacta is commercialising
non-therapeutic Affimer reagents through licensing to developers of
life sciences research tools and diagnostics.
This information is provided by RNS
The company news service from the London Stock Exchange
END
IOEUAVBRBVANRRR
(END) Dow Jones Newswires
June 01, 2017 03:56 ET (07:56 GMT)
Avacta (LSE:AVCT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Avacta (LSE:AVCT)
Historical Stock Chart
From Apr 2023 to Apr 2024